 |
|
|
|
|
| |
|
- Valeant receives FDA approval of Zelapar® for patients with Parkinson's Disease
- Valeant obtains FDA marketing approval for cannabinoid Cesamet™ to treat nausea and vomiting associated with cancer chemotherapy
- Valeant sells manufacturing facility in Warsaw, Poland
- Dermatological product line Kinerase is extended and its distribution through Nordstrom is launched
- Valeant announces strategic restructuring plan to reduce costs, accelerate earnings growth and focus research and development resources on select, late-stage pipeline products
- Valeant reports taribavirin VISER1 results, the first of two pivotal Phase 3 trials
- Valeant announces positive data from pradefovir mesylate Phase 2 study
- Courteney Cox signs contract for second year as Kinerase spokesperson
- Valeant receives FDA approval for less-restrictive labeling for Tasmar®
- Valeant acquires hepatitis-C drug Infergen® from Intermune, expanding the company's infectious disease franchise
- Valeant launches Zelapar® in the United States for Parkinson's disease
- Valeant mourns the death of Chairman Robert W. O'Leary
- Valeant launches Cesamet® in the United States and initiates a post-marketing clinical trial.
- Valeant reports VISER 2 results for Viramidine
- Valeant presents end-of-treatment results of DIRECT Trial for Infergen®
- Valeant initiates Infergen Phase 4 study
- Valeant and Metabasis Therapeutics license rights to Hepatitis B compound pradefovir to Schering-Plough
- Valeant's worldwide headquarters relocates to Aliso Viejo, California.
- Valeant sells discovery and preclinical assets to Ardea Biosciences.
|
|
|
|
